What is William Blair’s Forecast for MDxHealth Q1 Earnings?

MDxHealth SA (NASDAQ:MDXH) – Research analysts at William Blair boosted their Q1 2025 earnings estimates for shares of MDxHealth in a note issued to investors on Wednesday, February 26th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.15) per share for the quarter, up from their previous estimate of ($0.16). The consensus estimate for MDxHealth’s current full-year earnings is ($1.15) per share. William Blair also issued estimates for MDxHealth’s Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.07) EPS, FY2025 earnings at ($0.43) EPS and FY2026 earnings at ($0.34) EPS.

Separately, Piper Sandler cut their price target on MDxHealth from $8.00 to $6.00 and set an “overweight” rating on the stock in a research report on Thursday, November 7th.

MDxHealth Stock Down 6.0 %

Shares of NASDAQ:MDXH opened at $1.71 on Monday. The firm has a 50 day simple moving average of $2.00 and a 200-day simple moving average of $2.18. The company has a market capitalization of $80.86 million, a PE ratio of -1.13 and a beta of 1.34. MDxHealth has a twelve month low of $1.55 and a twelve month high of $3.85. The company has a current ratio of 1.54, a quick ratio of 1.45 and a debt-to-equity ratio of 3.14.

MDxHealth (NASDAQ:MDXH) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.07. The business had revenue of $24.74 million for the quarter, compared to the consensus estimate of $22.67 million. MDxHealth had a negative return on equity of 1,077.84% and a negative net margin of 49.52%.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently modified their holdings of the stock. AWM Investment Company Inc. raised its position in MDxHealth by 11.1% during the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company’s stock worth $11,189,000 after buying an additional 471,290 shares during the last quarter. MVM Partners LLC raised its stake in shares of MDxHealth by 3.3% during the 3rd quarter. MVM Partners LLC now owns 4,700,457 shares of the company’s stock worth $9,706,000 after buying an additional 150,000 shares in the last quarter. Samjo Management LLC lifted its holdings in shares of MDxHealth by 130.9% in the 4th quarter. Samjo Management LLC now owns 1,824,312 shares of the company’s stock valued at $4,324,000 after buying an additional 1,034,312 shares during the period. Perkins Capital Management Inc. boosted its stake in shares of MDxHealth by 31.6% in the fourth quarter. Perkins Capital Management Inc. now owns 983,475 shares of the company’s stock valued at $2,331,000 after buying an additional 236,100 shares in the last quarter. Finally, Northern Trust Corp acquired a new position in MDxHealth during the fourth quarter worth $1,033,000.

MDxHealth Company Profile

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.